A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis

@inproceedings{Wang2014API,
  title={A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis},
  author={Yan Wang and Yi-yi Yu and Wei Li and Yi Feng and Jun Hou and Yasheng Ji and Yihong Sun and Kun-tang Shen and Zhen-bin Shen and Xin-yu Qin and Tianshu Liu},
  booktitle={Cancer Chemotherapy and Pharmacology},
  year={2014}
}
Gastric cancer with para-aortic lymph node (PAN) involvement is regarded as advanced disease, and only chemotherapy is recommended from the guidelines. In unresectable cases, neoadjuvant chemotherapy could prolong survival if conversion to resectability could be achieved. The study was a single-arm phase II trial. Patients who were diagnosed with gastric cancer and PAN involvement (Stations No. 16a2/16b1) were treated with capecitabine and oxaliplatin combination chemotherapy every 3 weeks for… CONTINUE READING
12 Extracted Citations
21 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 12 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 21 references

Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement

  • IH Park, SY Kim, YW Kim
  • Cancer Chemother Pharmacol
  • 2011
Highly Influential
3 Excerpts

Compton CC (2010) the american Joint Committee on Cancer: the 7th edition of the aJCC cancer staging manual and the future of tnM

  • SB edge
  • ann Surg Oncol
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…